-
1 Comment
Vectus Biosystems Limited is currently in a long term uptrend where the price is trading 14.2% above its 200 day moving average.
From a valuation standpoint, the stock is 538.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1644.5.
Vectus Biosystems Limited's total revenue rose by 22759.1% to $50K since the same quarter in the previous year.
Its net income has dropped by 104.9% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 31.3% to $-692K since the same quarter in the previous year.
Based on the above factors, Vectus Biosystems Limited gets an overall score of 3/5.
| Exchange | AU |
|---|---|
| CurrencyCode | AUD |
| ISIN | AU000000VBS9 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 4M |
|---|---|
| Target Price | None |
| Beta | 1.04 |
| PE Ratio | None |
| Dividend Yield | None |
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure; VB4-A32 for the treatment of liver fibrosis; VB4-A79 for the treatment of lung fibrosis; and VB4-P5 for the treatment of renal fibrosis. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops Accugen consisting of AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for VBS.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
